

	Alameda Alliance for Health FORMULARY UPDATE <u>Effective 11/01/25, unless indicated below under Committee Actions.</u>
---	---

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the 09/16/25 meeting:

Therapeutic/Monograph Class Reviews	
• Bowel Prep Agents Class Review • Chelating Agents Class Review • Fluoroquinolones (oral) Class Review • Hepatitis C Agents Class Review • Respiratory Aids and Devices Class Review	• Rho Immune Globulins Class Review • VEGF Inhibitors Class Review • Ophthalmic Antibiotics and Antibiotic-Corticosteroid Combinations Class Review

The P&T Committee approved the following modifications to the formulary for the Alliance's Group Care programs.

Generic//Biosimilar Name & Strength/Dosage Form	Brand Name	Committee Actions
ribociclib succ (200 MG Dose) Oral Tablet Therapy Pack 200 MG	Kisqali (200 MG Dose) Oral Tablet Therapy Pack 200 MG	Add to formulary with Prior Authorization (PA)
ribociclib succ (400 MG Dose) Oral Tablet Therapy Pack 200 MG	Kisqali (400 MG Dose) Oral Tablet Therapy Pack 200 MG	Add to F- PA
ribociclib succ (600 MG Dose) Oral Tablet Therapy Pack 200 MG	Kisqali (600 MG Dose) Oral Tablet Therapy Pack 200 MG	Add to F-PA
palbociclib Oral Capsule 75 MG	Ibrance Oral Capsule 75 MG	Update to Non-Formulary (NF)
palbociclib Oral Capsule 100 MG	Ibrance Oral Capsule 100 MG	Update to NF
palbociclib Oral Capsule 125 MG	Ibrance Oral Capsule 125 MG	Update to NF
palbociclib Oral Tablet 125 MG	Ibrance Oral Capsule 125 MG	Update to NF
palbociclib Oral Tablet 100 MG	Ibrance Oral Tablet 100 MG	Update to NF
palbociclib Oral Tablet 75 MG	Ibrance Oral Tablet 75 MG	Update to NF
prucalopride succinate Oral Tablet 1 MG	Motegrity Oral Tablet 1 MG	Add generic to F- PA
prucalopride succinate Oral Tablet 2 MG	Motegrity Oral Tablet 2 MG	Add generic to F- PA
prucalopride succinate Oral Tablet 1 MG	Motegrity Oral Tablet 1 MG	Update brand to NF
prucalopride succinate Oral Tablet 2 MG	Motegrity Oral Tablet 2 MG	Update brand to NF
acoltremon Ophthalmic Solution 0.003 %	Tryptyr Ophthalmic Solution 0.003 %	Add to F- PA
filgrastim-txid Injection Solution Prefilled Syringe 480 MCG/0.8ML	Nypozi Injection Solution Prefilled Syringe 480 MCG/0.8ML	Add to F- PA

filgrastim-txid Injection Solution Prefilled Syringe 300 MCG/0.5ML	Nypozi Injection Solution Prefilled Syringe 300 MCG/0.5ML	Add to F- PA
ustekinumab-srlf Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML	Imuldosa Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML	Add to F- PA
ustekinumab-srlf Subcutaneous Solution Prefilled Syringe 90 MG/ML	Imuldosa Subcutaneous Solution Prefilled Syringe 90 MG/ML	Add to F- PA
tirzepatide Subcutaneous Solution 2.5 MG/0.5ML	Zepbound Subcutaneous Solution 2.5 MG/0.5ML	Update to NF
tirzepatide Subcutaneous Solution 5 MG/0.5ML	Zepbound Subcutaneous Solution 5 MG/0.5ML	Update to NF
norethin ace-eth estrad-FE Oral Tablet 1.5-30 MG- MCG	Feirza 1.5/30 Oral Tablet 1.5-30 MG-MCG	Add to Formulary (F)
norethin ace-eth estrad-FE Oral Tablet 1-20 MG-MCG	Feirza 1/20 Oral Tablet 1-20 MG-MCG	Add to F
ethynodiol diac-eth estradiol Oral Tablet 1-50 MG-MCG	Valtya 1/50 Oral Tablet 1-50 MG-MCG	Add to F
norethin-eth estradiol-Fe Oral Tablet Chewable 0.4- 35 MG-MCG	Xelria Fe Oral Tablet Chewable 0.4-35 MG- MCG	Add to F
copper intrauterine device	Miudella Intrauterine Copper Intrauterine Device	Add to F
ethinyl estradiol and norethindrone oral tablet chewable 0.8-25 mg-mcg	Galbriela Oral Tablet Chewable 0.8-25 MG- MCG	Add to F
promethazine HCl Oral Syrup 6.25 MG/5ML	Phenergan Plain Oral Syrup 6.25 MG/5ML	Add to F
desogestrel-ethinyl estradiol oral tablet 0.15- 0.03 mg	Averi Oral Tablet 0.15- 0.03 MG	Add to F
GNP naloxone HCl Nasal Liquid 4 MG/0.1ML	Narcan Nasal Liquid 4 MG/0.1ML	Add to F

tobramycin-dexAMETHasone Ophthalmic Ointment 0.3-0.1 %	TobraDex Ophthalmic Ointment 0.3-0.1 %	Add to F- PA with Quantity Limit 2 fills per 12 months
respiratory syncytial virus vaccine	MResvia Intramuscular Suspension Prefilled Syringe 50 MCG/0.5ML	Add to F-QL and Age Limit 0.5ml per lifetime; 18 years and older

PRIOR AUTHORIZATION GUIDELINE UPDATES

Anti-obesity medications	Rifamycin Antibiotics
Quantity Limit Exception	Medications for the treatment of Multi-Drug-Resistant Tuberculosis
Antiemetics	Palforzia
Ophthalmic Anti-inflammatory Immunomodulators	Specialty Biologic Agents
Dronabinol	Immunizations
White Blood Cell Stimulators	Vyalev
Constipation agents	Antifibrotic Respiratory Tract Agents
Mesalamine	Filspari
Scabicides and Pediculicides	

PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)	
Physician Administered Medication (PAD) Medical Benefit Guidelines	Topical Acne Agents
Off-label uses	Injectable/Infusible Bone-Modifying Agents for Oncology Indications
Safety Edit Exception	Alosetron (Lotronex)
Nuedexta (dextromethorphan/quinidine)	Viberzi (eluxadoline)
Cartilaginous Repair Agents	Rifabutin (Mycobutin)
Memantine ER (Namenda XR)	Tranexamic acid (Lysteda)
Vancomycin	Santyl Ointment
Multaq (dronedarone)	Topical Antibiotics
Erythropoiesis-Stimulating Agents	Injectable/Infusible Agents for Osteoporosis and Paget's Disease
Drugs for Gender Dysphoria for Less Than 21 Years Old	Vowst
Drugs for Gender Dysphoria For At Least 21 Years Old	Duvyzat
Corticosteroids for Ulcerative Colitis and Crohn's disease	Rho Kinase Inhibitors
Atovaquone-proguanil (Malarone)	Xolremdi
Intranasal Steroids	

**For questions, please contact the Alliance's Pharmacy Services department at:
(510) 747-4541.**